394 related articles for article (PubMed ID: 25231355)
1. Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes.
Tate M; Chong A; Robinson E; Green BD; Grieve DJ
Br J Pharmacol; 2015 Feb; 172(3):721-36. PubMed ID: 25231355
[TBL] [Abstract][Full Text] [Related]
2. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
Grieve DJ; Cassidy RS; Green BD
Br J Pharmacol; 2009 Aug; 157(8):1340-51. PubMed ID: 19681866
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.
Anagnostis P; Athyros VG; Adamidou F; Panagiotou A; Kita M; Karagiannis A; Mikhailidis DP
Diabetes Obes Metab; 2011 Apr; 13(4):302-12. PubMed ID: 21205117
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular biology of the incretin system.
Ussher JR; Drucker DJ
Endocr Rev; 2012 Apr; 33(2):187-215. PubMed ID: 22323472
[TBL] [Abstract][Full Text] [Related]
5. GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice.
Romera I; Rubio-de Santos M; Artola S; Suárez Fernández C; Conget I
Adv Ther; 2023 Apr; 40(4):1418-1429. PubMed ID: 36821026
[TBL] [Abstract][Full Text] [Related]
6. Incretins and cardiovascular disease: to the heart of type 2 diabetes?
Solini A; Tricò D; Del Prato S
Diabetologia; 2023 Oct; 66(10):1820-1831. PubMed ID: 37542009
[TBL] [Abstract][Full Text] [Related]
7. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
Camafort-Babkowski M
Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622
[TBL] [Abstract][Full Text] [Related]
8. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis.
Hogan AE; Tobin AM; Ahern T; Corrigan MA; Gaoatswe G; Jackson R; O'Reilly V; Lynch L; Doherty DG; Moynagh PN; Kirby B; O'Connell J; O'Shea D
Diabetologia; 2011 Nov; 54(11):2745-54. PubMed ID: 21744074
[TBL] [Abstract][Full Text] [Related]
10. Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes.
Cariou B
Diabetes Metab; 2012 Oct; 38(4):298-308. PubMed ID: 22672960
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor.
Helmstädter J; Keppeler K; Küster L; Münzel T; Daiber A; Steven S
Br J Pharmacol; 2022 Feb; 179(4):659-676. PubMed ID: 33764504
[TBL] [Abstract][Full Text] [Related]
13. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
14. Potential cardiovascular effects of incretin-based therapies.
Deacon CF; Marx N
Expert Rev Cardiovasc Ther; 2012 Mar; 10(3):337-51. PubMed ID: 22390806
[TBL] [Abstract][Full Text] [Related]
15. The effect of glucagon-like peptide 1 on cardiovascular risk.
Sivertsen J; Rosenmeier J; Holst JJ; Vilsbøll T
Nat Rev Cardiol; 2012 Jan; 9(4):209-22. PubMed ID: 22290234
[TBL] [Abstract][Full Text] [Related]
16. Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes.
Verge D; López X
Curr Diabetes Rev; 2010 Jul; 6(4):191-200. PubMed ID: 20380625
[TBL] [Abstract][Full Text] [Related]
17. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B; Bonnard C; Renard E
Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
[TBL] [Abstract][Full Text] [Related]
18. Impact of glucagon-like peptide-1 on endothelial function.
Sjöholm A
Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():19-25. PubMed ID: 19878258
[TBL] [Abstract][Full Text] [Related]
19. Vascular protective effects of diabetes medications that mimic or increase glucagon-like peptide-1 activity.
Motta AJ; Koska J; Reaven P; Migrino RQ
Recent Pat Cardiovasc Drug Discov; 2012 Apr; 7(1):2-9. PubMed ID: 22280335
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
